Assessment of lung deposition and pharmacokinetics in 12 lung transplanted patients after inhalation of a novel liposomal ciclosporin a (CsA) formulation by the eFlow electronic nebuliser Source: Eur Respir J 2007; 30: Suppl. 51, 29s Year: 2007
Dry powder inhaled ribavirin in healthy volunteers: safety, tolerability, lung and systemic pharmacokinetics Source: International Congress 2017 – From microbiology to clinical work Year: 2017
Pulmonary pharmacokinetics and safety of nebulised duramycin in healthy male volunteers Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009
Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009
Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Pharmacokinetic differences between inhaled treprostinil and inhaled iloprost in severe pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004
Inhaled liposomal treprostinil (L606) shows extended release in healthy volunteer, as well as prolongs pharmacological effect in hypoxia-induced rat. Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020
Effects of low dose inhaled theophylline (ADC4022) co-administered with budesonide on inflammatory markers, lung function, and quality of life in COPD patients Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
The pharmacokinetics of inhaled NVA237 in COPD patients Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Comparison of pulmonary and systemic absoption of two HFA formulations of salmeterol in healthy subjects Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Low systemic exposure of NVA237, an inhaled once-daily anticholinergic bronchodilator, in healthy humans Source: Eur Respir J 2006; 28: Suppl. 50, 661s Year: 2006
Rapid switch from epoprostenol (EPO) to intravenous treprostinil (TRE) in patients with pulmonary arterial hypertension (PAH): safety, efficacy, and treatment satisfaction Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009
Tolerability and pharmacokinetics of inhaled bimosiamose in healthy human volunteers Source: Eur Respir J 2006; 28: Suppl. 50, 332s Year: 2006
A placebo-controlled study of liposomal amikacin for inhalation nebulized once daily in the treatment of bronchiectasis patients with chronic pseudomonas aeruginosa lung infection Source: Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa Year: 2009
Safety, tolerability and pharmacokinetics (PK) of AZD8154 (a selective PI3K?d inhibitor) after single ascending inhaled doses in healthy volunteers Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019
Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections Year: 2010
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
Population pharmacokinetics of nebulized arformoterol in subjects with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 427s Year: 2006
Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021